Larimar Therapeutics, Inc.
LRMRHealthcare|Biotechnology|US
$2.39
+0.07 (+3.02%)
DCF Value
$1.06
Tangible Book / Share
$1.23
Cash / Share
$1.50
About
Headquartered in Bala Cynwyd, Pennsylvania, Larimar Therapeutics, Inc. operates as a clinical-stage biotechnology firm. Its core mission involves crafting therapies for rare diseases, leveraging a distinctive cell-penetrating peptide technology platform. The company's foremost experimental therapy, CTI-1601, is presently undergoing Phase 1 clinical trials. This drug candidate is being developed to combat Friedreich's ataxia, a genetic illness that is rare, relentlessly progressive, and ultimately fatal.
Stock Price
-31.1%(1Y)
1M
-11.5%
3M
-42.5%
6M
-39.8%
YTD
-37.3%
1Y
-32.7%
3Y
-14.3%
5Y
-81.6%
Pipeline Summary
8 total trials3
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
Completed: 5Recruiting: 2Terminated: 1
Active Trials (2)
An Open-Label Study of CTI-1601 in Subjects With Friedreich's Ataxia
NCT06447025Friedreich Ataxia
Phase 2Recruiting
Enrollment: 85 participants
A Study to Evaluate the Efficacy and Safety of Subcutaneous Nomlabofusp in Subjects With Friedreich's Ataxia
NCT07778836Friedreich Ataxia
Phase 3Recruiting
Enrollment: 150 participants
Key Facts
Market Cap$248.3M
Employees71 (+9% YoY)
CEOCarole S. Ben-Maimon
IPO DateJun 19, 2014
Beta0.69
52-Week Range$1.915 – $6.42
Avg Volume1,411,262
ExchangeNASDAQ
Websitelarimartx.com
Ownership
Float55.7%
Shares Outstanding103.9M
Recent Insider Trades
Harlow John B. Jr.AWARD
Sep 29, 2026800,000 shares @ $3.14
Harlow John B. Jr.AWARD
Sep 29, 202650,000 shares
Harlow John B. Jr.OTHER
Sep 29, 20260 shares
Hamilton Thomas EdwardBUY
Jul 6, 202650,000 shares @ $3.34
Flynn James EAWARD
May 19, 202655,150 shares @ $3.33
Peers
Recent News
Larimar Therapeutics Announces Three Poster Presentations for the Nomlabofusp Program at the Upcoming International Congress for Ataxia Research
Nov 5, 2026 · globenewswire.com
Larimar Therapeutics to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
Nov 4, 2026 · globenewswire.com
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
Oct 10, 2026 · marketbeat.com
Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Oct 5, 2026 · zacks.com
Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
Sep 29, 2026 · globenewswire.com
Data last updated: Nov 9, 2026, 04:20 AM